Business
Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit
HOUSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing
About this update from Marker Therapeutics, Inc.
[{"type":"text","content":"HOUSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics, will present at the Citizens JMP Hematology and Oncology Summit. This investor event will be held virtually on December 2, 2024. Dr. Vera will present an overview of Marker’s technology and clinical developments on Monday, December 2, 2024, at 11 AM EST. Details of the presentation are as follows: Event:The Citizens JMP Hematology and Oncology SummitDate: December 2, 2024, at 11 AM ESTLocation:Virtual EventWebcast:https://wsw.com/webcast/jmp66/register.aspx?conf=jmp66&page=mrkr&url=https://wsw.com/webcast/jmp66/mrkr/1699092 After the event, Dr. Vera’s presentation will be available for replay on the Company’s IR website under Events & Presentations. During the conference, Dr. Vera and members of the Marker management team will conduct one-on-one meetings with registered investors, showcasing the Company’s business and clinical development. About Marker Therapeutics, Inc.Marker Therapeutics, Inc. is a Houston, TX-based clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors. Clinical trials that enrolled more than 200 patients across various hematological and solid tumor indications showed that the Company’s autologous and allogeneic multiTAA-specific T cell products were well tolerated and demonstrated durable clinical responses. Marker’s goal is to introduce novel T cell therapies to the market and improve patient outcomes. To achieve these objectives, the Company prioritizes the preservation of financial resources and focuses on operational excellence. Marker’s unique T cell platform is strengthened by non-dilutive funding from U.S. state and federal agencies supporting cancer research. To receive future press releases via email, please visit: https://www.markertherapeutics.com/email-alerts. Forward-Looking StatementsThis release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Liti...